The HCPCS level II code A9616 goes into effect on October 1 for the PSMA PET preparation kit, which received FDA approval in March.
The Centers for Medicare and Medicaid Services (CMS) has provided a permanent HCPCS code for the use of the PSMA PET agent Gozellix, a preparation kit for the gallium-68 (68Ga) gozetotide injection.
The HCPCS level II code A9616 will go into effect on October 1, 2025, according to Telix Pharmaceuticals, the manufacturer of Gozelliz.
In combination with 68Ga radiolabeling, Gozellix was approved by the Food and Drug Administration (FDA) earlier this year for use in PSMA PET for men with suspected metastatic prostate cancer (PCa) who are eligible for initial definitive therapy. The PSMA PET prep product is also indicated for use in men with suspected biochemical recurrence of PCa.
"Being granted a HCPCS code marks a significant step forward in Telix's mission to improve access to precision medicine imaging for prostate cancer patients across the United States, regardless of their location,” noted Kevin Richardson, the chief executive officer of precision medicine for Telix Pharmaceuticals. “It is also an important enabler for commercial scale-up and reimbursement of Gozellix in the U.S. as we bring our next-generation PSMA PET imaging agent to market."
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Large Medicare Study Shows Black Men Less Likely to Receive PET and MRI for Prostate Cancer Imaging
August 1st 2025An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
August 1st 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
August 1st 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.